The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS), another multicenter placebo-controlled trial, proved that IL-1β targeted therapy can prevent recurrent cardiovascular events to some extent [48]. The gene discussed is IL1B; the disease is Venous thrombosis.